ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2375

Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Abstract Number: 1178

Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?
Abstract Number: 0216

Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?
Abstract Number: 0690

Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database
Abstract Number: 2575

Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Abstract Number: 2037

Can Tofacitinib Be the Saviour in Treatment of Refractory IgG4-Related Disease : A Multicentre Experience from India
Abstract Number: 0369

Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Abstract Number: 0480

Can’t Sleep, Won’t Sleep: A Systematic Review and Meta-Analysis of Insomnia Prevalence in 70,105 Rheumatoid Arthritis Patients
Abstract Number: 2039

Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience
Abstract Number: 2069

Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Abstract Number: 0699

Cardiac Biomarkers for Predicting Cardiopulmonary Toxicity of Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis
Abstract Number: 0331

Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Abstract Number: 0313

Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Abstract Number: 0598

Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Abstract Number: 2275

Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].